Septerna (NASDAQ:SEPN) Trading Up 5.7% – Time to Buy?

Septerna, Inc. (NASDAQ:SEPN)’s stock price rose 5.7% during trading on Wednesday . The company traded as high as $19.39 and last traded at $19.76. Approximately 31,567 shares were traded during trading, a decline of 84% from the average daily volume of 193,123 shares. The stock had previously closed at $18.70.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Finally, Wells Fargo & Company initiated coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price objective on the stock.

Septerna Stock Up 4.6 %

The company has a 50-day simple moving average of $22.57.

Insider Buying and Selling at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Investors Weigh In On Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,095 shares of the company’s stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.